A novel phosphoramide compound, DCZ0805, shows potent anti-myeloma activity via the NF-κB pathway

doi:10.1186/s12935-021-01973-1

	A novel phosphoramide compound, DCZ0805, shows potent anti-myeloma activity via the NF-κB pathway
	Gao,Xuejie 1; Li,Bo 2; Ye,Anqi 3; Wang,Houcai 1; Xie,Yongsheng 1; Yu,Dandan 1; Xu,Zhijian 2; Shi,Bingqing 1; Zhang,Hui 1; Feng,Qilin 1
刊名	Cancer Cell International
	2021-05-30
卷号	21 期号:1
关键词	Multiple myeloma Anti-tumor activity NF-κB
DOI	10.1186/s12935-021-01973-1
通讯作者	Shi,Jumei(shijumei@tongji.edu.cn) ; Zhu,Weiliang(wlzhu@simm.ac.cn)
英文摘要	AbstractBackgroundMultiple myeloma (MM) is a highly aggressive and incurable clonal plasma cell disease with a high rate of recurrence. Thus, the development of new therapies is urgently needed. DCZ0805, a novel compound synthesized from osalmide and pterostilbene, has few observed side effects. In the current study, we intend to investigate the therapeutic effects of DCZ0805 in MM cells and elucidate the molecular mechanism underlying its anti-myeloma activity.MethodsWe used the Cell Counting Kit-8 assay, immunofluorescence staining, cell cycle assessment, apoptosis assay, western blot analysis, dual-luciferase reporter assay and a tumor xenograft mouse model to investigate the effect of DCZ0805 treatment both in vivo and in vitro.ResultsThe results showed that DCZ0805 treatment arrested the cell at the G0/G1 phase and suppressed MM cells survival by inducing apoptosis via extrinsic and intrinsic pathways. DCZ0805 suppressed the NF-κB signaling pathway activation, which may have contributed to the inhibition of cell proliferation. DCZ0805 treatment remarkably reduced the tumor burden in the immunocompromised xenograft mouse model, with no obvious toxicity observed.ConclusionThe findings of this study indicate that DCZ0805 can serve as a novel therapeutic agent for the treatment of MM.
语种	英语
出版者	BioMed Central
WOS记录号	BMC:10.1186/S12935-021-01973-1
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/296472]
专题	中国科学院上海药物研究所
通讯作者	Shi,Jumei; Zhu,Weiliang
作者单位	1.Tongji University School of Medicine; Department of Hematology, Shanghai Tenth People’s Hospital 2.Shanghai Institute of Materia Medica, Chinese Academy of Sciences; CAS Key Laboratory of Receptor Research, Drug Discovery and Design Center 3.Shanghai JiaoTong University School of Medicine; Shanghai Children’s Medical Center
推荐引用方式 GB/T 7714	Gao,Xuejie,Li,Bo,Ye,Anqi,et al. A novel phosphoramide compound, DCZ0805, shows potent anti-myeloma activity via the NF-κB pathway[J]. Cancer Cell International,2021,21(1).
APA	Gao,Xuejie.,Li,Bo.,Ye,Anqi.,Wang,Houcai.,Xie,Yongsheng.,...&Zhu,Weiliang.(2021).A novel phosphoramide compound, DCZ0805, shows potent anti-myeloma activity via the NF-κB pathway.Cancer Cell International,21(1).
MLA	Gao,Xuejie,et al."A novel phosphoramide compound, DCZ0805, shows potent anti-myeloma activity via the NF-κB pathway".Cancer Cell International 21.1(2021).